SightGlass Vision Presents New Myopia Control Science and Clinical Insights at 2023 BCLA Conference

With a goal to improve myopia control adoption and outcomes, SightGlass Vision is presenting a range of new scientific studies and professional education at the 2023 BCLA Clinical Conference taking place from June 9-11 in Manchester, England.

Three-Year Myopia Control Efficacy of DOT Spectacle Lenses in Young Children (Laughton D., et al.) centers on a sub-group 6-to-7-year-olds who participated in the company’s pivotal CYPRESS clinical trial, with investigators noting expectations of highly progressive myopia and a paucity of efficacy data for this age group. After 3 years, myopia progression among these young children was limited to <1.00 D in 60% of Diffusion Optics Technology 0.2 spectacle lens wearers compared to 21% of control lens wearers. This data—shared for the first time in Manchester—further support previously announced safety and efficacy outcomes. 

"Reliability of Quality of Vision Questionnaire Results from Children" (McParland M., et al.) assessed pediatric application of the Quality of Vision (QoV) questionnaire, which is more commonly used for adult refractive surgery and intraocular lens research. Investigators abbreviated the standard QoV instrument to focus on glare, hazy vision, and halos, then analyzed responses from CYPRESS clinical trial participants and from their parents/guardians across 3 years. The greater consistency of within-child agreement compared to parent-child response agreement suggests that parents may under-report their children’s experiences, while also affirming that children as young as age 6 can share meaningful QoV-derived insights to help inform clinical decisions.

Peripheral Visual Function with DOT Spectacle Lenses for Myopia Control(Aboualizadeh E., et al.) debuts at the BCLA meeting, tapping into the rich CYPRESS data set to review long-term changes in peripheral visual acuity (VA) after 3 years of Diffusion Optics Technology spectacle lens wear. Compared to the baseline, peripheral VA improved or remained stable, with no significant differences between the DOT and standard single-vision groups. 

SightGlass Vision has also organized one of eight prominent peer review track sessions at the conference on Saturday: How Do Myopia Management Therapies Work and Does It Matter?, led by global myopia experts Prof. Nicola Logan and Prof. James Wolffsohn. Anticipated high demand for the session requires pre-booking from attendees.

Spectacle lenses with SightGlass Vision Diffusion Optics Technology use thousands of micro-dots to softly scatter light to reduce contrast on the retina, a unique mechanism of action to control myopia progression in children. Over the last 18 months, this patent-protected technology with clinically proven efficacy[1],[2],[3]made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.

References

[1] Control of myopia using Diffusion Optics Technology™ spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005 

[2] Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408. 

[3] Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.